Efficacy of combination treatment using YHO-1701, an orally active STAT3 inhibitor, with molecular-targeted agents on cancer cell lines

Antitumor activity of a novel oral STAT3 inhibitor YHO‐1701

(2020) Fukiko Nishisaka et al.   CANCER SCIENCE

Brusatol suppresses STAT3-driven metastasis by downregulating epithelial-mesenchymal transition in hepatocellular carcinoma

(2020) Jong Hyun Lee et al.   Journal of Advanced Research

The pleiotropic role of transcription factor STAT3 in oncogenesis and its targeting through natural products for cancer prevention and therapy

(2020) Manoj Garg et al.   MEDICINAL RESEARCH REVIEWS

Survivin as a Diagnostic and Therapeutic Marker for Thyroid Cancer

(2019) Mohammad-Reza Mahmoudian-Sani et al.   PATHOLOGY RESEARCH AND PRACTICE

Application of Prostate Cancer Models for Preclinical Study: Advantages and Limitations of Cell Lines, Patient-Derived Xenografts, and Three-Dimensional Culture of Patient-Derived Cells

(2019) Takeshi Namekawa et al.   Cells

The role of Survivin as a biomarker and potential prognostic factor for breast cancer

(2019) Glaucia Luciano da Veiga et al.   Revista da Associacao Medica Brasileira

Predicting Synergism of Cancer Drug Combinations Using NCI-ALMANAC Data

(2019) Pavel Sidorov et al.   Frontiers in Chemistry

Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients

(2018) J Remon et al.   ANNALS OF ONCOLOGY

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

(2017) Imane Chaib et al.   JNCI-Journal of the National Cancer Institute

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

(2017) Imane Chaib et al.   JNCI-Journal of the National Cancer Institute

Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs

(2016) Richard Bayliss et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer

(2016) Masayoshi Miyawaki et al.   MOLECULAR CANCER RESEARCH

Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?

(2016) Witthawat Ariyawutyakorn et al.   Journal of Cancer

Brassinin inhibits STAT3 signaling pathway through modulation of PIAS-3 and SOCS-3 expression and sensitizes human lung cancer xenograft in nude mice to paclitaxel

(2015) Jong Hyun Lee et al.   Oncotarget

Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells

(2015) Azusa Tanimoto et al.   Oncotarget

Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer

(2014) AKIHIRO KOGITA et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Patient-derived models of acquired resistance can identify effective drug combinations for cancer

(2014) Adam S. Crystal et al.   SCIENCE

STAT3 in Cancer—Friend or Foe?

(2014) Hai-Feng Zhang et al.   Cancers

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

Deguelin Action Involves c-Met and EGFR Signaling Pathways in Triple Negative Breast Cancer Cells

(2013) Rajeshwari Mehta et al.   PLoS One

Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells

(2012) J Tanizaki et al.   BRITISH JOURNAL OF CANCER

Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer

(2012) Robert C. Doebele et al.   CLINICAL CANCER RESEARCH

The Promise of Patient-Derived Xenografts: The Best Laid Plans of Mice and Men

(2012) S. Kopetz et al.   CLINICAL CANCER RESEARCH

STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers

(2012) XIAOCHUN WANG et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

(2012) R. Katayama et al.   Science Translational Medicine

A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors

(2011) T. Sasaki et al.   CANCER RESEARCH

Requirement of the Acquired Immune System in Successful Cancer Chemotherapy With cis-Diamminedichloroplatinum (II) in a Syngeneic Mouse Tumor Transplantation Model

(2011) Keisuke Taniguchi et al.   JOURNAL OF IMMUNOTHERAPY

JAK1 Activates STAT3 Activity in Non-Small-Cell Lung Cancer Cells and IL-6 Neutralizing Antibodies Can Suppress JAK1-STAT3 Signaling

(2011) L. Song et al.   MOLECULAR CANCER THERAPEUTICS

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Roles of the Ribosomal Protein S19 Dimer and Chemically Induced Apoptotic Cells as a Tumor Vaccine in Syngeneic Mouse Transplantation Models

(2010) Keisuke Taniguchi et al.   JOURNAL OF IMMUNOTHERAPY

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

(2010) Young Lim Choi et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Primary Xenograft Model of Small-Cell Lung Cancer Reveals Irreversible Changes in Gene Expression Imposed by Culture In vitro

(2009) V. C. Daniel et al.   CANCER RESEARCH

EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

(2008) J. P. Koivunen et al.   CLINICAL CANCER RESEARCH